PhoenixBio Co.,Ltd. Logo

PhoenixBio Co.,Ltd.

CRO providing humanized liver mouse models and testing services for preclinical drug development.

6190 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
東広島市鏡山三丁目4番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PhoenixBio is a contract research organization (CRO) specializing in preclinical drug development services. The company's core offering is the proprietary PXB-Mouse®, a chimeric mouse model whose liver is highly repopulated (over 70%) with functional human hepatocytes. This humanized liver model serves as a critical translational tool for pharmaceutical and biotechnology companies, enabling more accurate in vivo predictions of human drug metabolism, toxicity, and efficacy. PhoenixBio provides both the PXB-Mouse® for client-led research and a comprehensive suite of in-house contract testing services. As a leading global supplier with a stable production capacity and extensive scientific validation, the company supports the advancement of new therapeutics from discovery to clinical application.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-01 04:29
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2025-06-25 04:07
Governance Information
内部統制報告書-第24期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-25 04:04
Registration Form
確認書
Japanese 8.0 KB
2025-06-25 04:02
Annual Report
有価証券報告書-第24期(2024/04/01-2025/03/31)
Japanese 912.3 KB
2025-05-23 05:02
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2025-05-14 09:55
Audit Report / Information
臨時報告書
Japanese 20.1 KB
2025-03-03 02:24
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
Regulatory News Service
確認書
Japanese 8.0 KB
2024-11-14 08:04
Interim Report
半期報告書-第24期(2024/04/01-2025/03/31)
Japanese 165.5 KB
2024-07-02 02:35
Regulatory News Service
臨時報告書
Japanese 18.4 KB
2024-07-01 07:59
Regulatory News Service
臨時報告書
Japanese 21.4 KB
2024-06-27 03:06
Governance Information
内部統制報告書-第23期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-27 03:04
Registration Form
確認書
Japanese 8.0 KB
2024-06-27 03:03
Annual Report
有価証券報告書-第23期(2023/04/01-2024/03/31)
Japanese 886.1 KB
2024-02-14 07:51
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all PhoenixBio Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PhoenixBio Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea 149300
Arterra Bioscience Logo
Develops natural active ingredients via biotechnology for cosmetic, pharma, and food sectors.
Italy ABS
ASUA Inc. Logo
Consulting and solutions provider enhancing logistics safety and efficiency with IoT and telecom.
Japan 246A
Licenses patented material IP (MST®) to create higher-performance, lower-power semiconductors.
United States of America ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan 6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia N/A
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan 6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.